Pamela Vig - 24 Jun 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
24 Jun 2024
Net transactions value
-$949,285
Form type
4
Filing time
25 Jun 2024, 17:15:54 UTC
Previous filing
16 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $89,721 +30,559 +112% $2.94 57,965 24 Jun 2024 Direct
transaction MIRM Common Stock Sale $1,039,006 -30,559 -53% $34.00 27,406 24 Jun 2024 Direct F1
holding MIRM Common Stock 75,000 24 Jun 2024 By The Vig-Ancock Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Options Exercise $0 -30,559 -20% $0.000000 125,691 24 Jun 2024 Common Stock 30,559 $2.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted in March 2024.
F2 The stock option is fully vested.